L3VLUP
ProSign in

IRMD · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IRMDVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IRMD
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterIRMDVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 20211 holders, $1.1m35 holders, $10.1bn
Q4 20211 holders, $32m28 holders, $12.4bn
Q1 20221 holders, $6.4m23 holders, $16.1bn
Q2 20221 holders, $5.6m25 holders, $18.1bn
Q3 20221 holders, $5.0m22 holders, $18.4bn
Q4 20221 holders, $4.7m28 holders, $18.4bn
Q1 20231 holders, $7.1m26 holders, $21.4bn
Q2 20231 holders, $8.7m27 holders, $24.7bn
Q3 20233 holders, $34m33 holders, $24.3bn
Q4 20233 holders, $36m32 holders, $28.6bn
Q1 20241 holders, $6.9m31 holders, $29.8bn
Q2 20241 holders, $6.3m29 holders, $33.4bn
Q3 20241 holders, $6.9m27 holders, $33.5bn
Q4 20241 holders, $7.8m26 holders, $28.5bn
Q1 20251 holders, $8.2m21 holders, $35.4bn
Q2 20252 holders, $11m21 holders, $32.3bn
Q3 20253 holders, $47m22 holders, $25.9bn
Q4 20253 holders, $62m26 holders, $31.8bn
Q1 20264 holders, $60m25 holders, $31.8bn
Q2 20262 holders, $38m26 holders, $34.6bn
IRMD

Iradimed Corp

Holders
3
Reported value
$47m
Buyers
1
Sellers
2

Breadth -1 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
22
Reported value
$25.9bn
Buyers
13
Sellers
10

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 24 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IRMD (2)

Acadian Asset Management LLC, Polen Capital Management LLC

Only VRTX (21)

AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Freestone Grove Partners LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →